Publications by authors named "Codrina Mihaela Ancuta"
This study investigates the combined treatment of secukinumab (SECU) and magnolol (MAGN) in a mouse model of LPS-induced ALI overlapped with allergic pulmonary inflammation, aiming to better understand the mechanism behind this pathology and to assess the therapeutic potential of this novel approach in addressing the severity of ALI. The combined treatment reveals intricate immunomodulatory effects. Both treatments inhibit IL-17 and promote M2 macrophage polarization, which enhances anti-inflammatory cytokine production such as IL-4, IL-5, IL-10, and IL-13, crucial for lung repair and inflammation resolution.
View Article and Find Full Text PDFArticle Synopsis
- Neutrophils play a significant role in severe asthma and acute lung injury (ALI) through IL-17 stimulation, promoting an oxidative environment.
- The study compared the effects of Secukinumab (SECU) with Dexamethasone (DEXA) in mice with asthma exacerbated by LPS, focusing on various immune response cytokines.
- Results showed that both treatments altered cytokine levels, with SECU uniquely inhibiting IL-5 and decreasing Th17 responses, while DEXA had different effects on Th1 and Th2 cytokines.
Objective: To assess intercentre variability in the ACR core set measures, DAS28 based on three variables (DAS28v3) and Routine Assessment of Patient Index Data 3 in a multinational study.
Methods: Seven thousand and twenty-three patients were recruited (84 centres; 30 countries) using a standard protocol in the Quantitative Standard Monitoring of Patients with RA study. Analysis of variance (ANOVA) and mixed-effect analysis of covariance models were used to model the relationship between study centre and different patient-reported and physician-reported RA activity measures.